Aurobindo Pharma Limited

rs,

(E), MUMBAI ·400 051 To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI ·400 001 Company Code No. AUROPHARMA Company Code No. 524804

Rs 6,235.9 crore

f the quarter 5 Consolidated Financial & Business Highlights – Q1 FY23 Revenue from operations at Rs 6,235.9 crore, increased by 9.4% QoQ, US revenues at US$ 386 Million Research & Development (R&D) spend at Rs 31

9.4%

inancial & Business Highlights – Q1 FY23 Revenue from operations at Rs 6,235.9 crore, increased by 9.4% QoQ, US revenues at US$ 386 Million Research & Development (R&D) spend at Rs 310 crore in Q1FY23,

386 Million

s – Q1 FY23 Revenue from operations at Rs 6,235.9 crore, increased by 9.4% QoQ, US revenues at US$ 386 Million Research & Development (R&D) spend at Rs 310 crore in Q1FY23, 5% of revenue Vs. Rs. 358 crore in Q

Rs 310 crore

crore, increased by 9.4% QoQ, US revenues at US$ 386 Million Research & Development (R&D) spend at Rs 310 crore in Q1FY23, 5% of revenue Vs. Rs. 358 crore in Q1FY22, 6.3% of revenue EBIDTA before Forex and Ot

5%

QoQ, US revenues at US$ 386 Million Research & Development (R&D) spend at Rs 310 crore in Q1FY23, 5% of revenue Vs. Rs. 358 crore in Q1FY22, 6.3% of revenue EBIDTA before Forex and Other income at

Rs. 358 crore

at US$ 386 Million Research & Development (R&D) spend at Rs 310 crore in Q1FY23, 5% of revenue Vs. Rs. 358 crore in Q1FY22, 6.3% of revenue EBIDTA before Forex and Other income at Rs 964.7 crore; EBITDA margin

6.3%

ch & Development (R&D) spend at Rs 310 crore in Q1FY23, 5% of revenue Vs. Rs. 358 crore in Q1FY22, 6.3% of revenue EBIDTA before Forex and Other income at Rs 964.7 crore; EBITDA margin is at 15.5% Ne

Rs 964.7 crore

of revenue Vs. Rs. 358 crore in Q1FY22, 6.3% of revenue EBIDTA before Forex and Other income at Rs 964.7 crore; EBITDA margin is at 15.5% Net Profit at Rs 520.5crore Basic & Diluted EPS is Rs 8.88 per share

15.5%

Y22, 6.3% of revenue EBIDTA before Forex and Other income at Rs 964.7 crore; EBITDA margin is at 15.5% Net Profit at Rs 520.5crore Basic & Diluted EPS is Rs 8.88 per share Net organic capex for the

Rs 520.5crore

EBIDTA before Forex and Other income at Rs 964.7 crore; EBITDA margin is at 15.5% Net Profit at Rs 520.5crore Basic & Diluted EPS is Rs 8.88 per share Net organic capex for the quarter ~US$ 61 Million includ

Rs 8.88

at Rs 964.7 crore; EBITDA margin is at 15.5% Net Profit at Rs 520.5crore Basic & Diluted EPS is Rs 8.88 per share Net organic capex for the quarter ~US$ 61 Million including investment of ~US$ 8 Million